NPS Pharmaceuticalsstock price jumped over 25% when the FDA released upbeat briefing materials on the company’s pipeline candidate Natpara ahead of the review by its Endocrinologic and Metabolic Drugs Advisory …
He says, following European regulatory submission of Preos (expected in the next week) and Preos' NDA submission in late first-quarter/early second-quarter, he doesn't see any substantial catalysts to drive NPS
Click here to learn more about the investigation http://brodsky-smith.com/876-npsp-nps-pharmaceuticals
NPSP) is up huge in regular trading on Wednesday, due to positive preliminary results of a clinical trial. The FDA has posted the briefing materials prior to the meeting for approval. The trial has not yet been approved by the …
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a price of $14.53 per share to the public. All of the shares are being …
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a global biopharmaceutical company pioneering and delivering …
NPSP has a 1-year high of $45.75 and a 1-year low of $22.11. The stock’s 50-day moving average is $38.38 and it’s 200-day moving average is $30.74. On the ratings front, NPS Pharmaceuticals has been the subject of a …
following a rally in its stock. Shire PLC, Dublin-based specialty pharmaceutical company, is considered to be prime contestant in the process, given its expression of interest to takeover NPS Pharmaceuticals, Inc. …
to Section 2 of the Note, the outstanding principal and accrued interest on the Note shall be convertible into …
Definitive